FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2939723251> ?p ?o ?g. }

• W2939723251 endingPage "727" @default.
• W2939723251 startingPage "719" @default.
• W2939723251 abstract "Hepatoblastoma treatment with curative intent requires surgical resection, but only about a third of newly diagnosed patients with hepatoblastoma have resectable disease at diagnosis. Patients who have upfront resection typically receive a total of 4-6 cycles of adjuvant chemotherapy post-surgery, with the combination of cisplatin, fluorouracil, and vincristine. We aimed to investigate whether event-free survival in children with hepatoblastoma who had complete resection at diagnosis could be maintained with two cycles of adjuvant chemotherapy.In this Children's Oncology Group, multicentre, phase 3 trial, patients were enrolled in four risk groups on the basis of Evans surgical stage, tumour histology, and levels of α-fetoprotein at diagnosis to receive risk-adapted therapy. Here, we report on the low-risk stratum of the trial. Eligible patients were younger than 21 years and had histologically confirmed, stage I or II hepatoblastoma without 100% pure fetal stage I or small-cell undifferentiated histology; elevated serum α-fetoprotein level (>100 ng/mL); a complete resection at diagnosis; at least 50% Karnofsky (patients >16 years) or Lansky (patients ≤16 years) performance status; and had received no previous chemotherapy or other hepatoblastoma-directed therapy. Patients received two 21-day cycles of cisplatin, fluorouracil, and vincristine within 42 days of resection, consisting of cisplatin (100 mg/m2 per dose or 3·3 mg/kg per dose for children <10 kg) intravenously over 6 h on day 1; fluorouracil (600 mg/m2 per dose or 20 mg/kg per dose for children <10 kg) intravenous push on day 2; and vincristine (1·5 mg/m2 per day to a maximum dose of 2 mg, or 0·05 mg/kg per day for children <10 kg) intravenous push on days 2, 9, and 16. The primary outcome was investigator-assessed event-free survival. As prespecified by protocol, we analysed the primary endpoint 6 years after enrolment (cutoff date June 30, 2017). This trial is registered with ClinicalTrials.gov, number NCT00980460, and is now permanently closed to accrual.Between May 18, 2010, and May 28, 2014, 51 patients in 32 centres in two countries were enrolled into the low-risk stratum of this trial, of whom 49 received c hemotherapy treatment after surgery and were evaluable for activity and safety. Median follow-up time for all evaluable patients was 42 months (IQR 36-62). 4-year event-free survival was 92% (95% CI 79-97) and 5-year event-free survival was 88% (72-95). Two (4%) of 49 patients had surgical complications (bile leaks). The most common grade 3-4 adverse events were febrile neutropenia in seven (14%) patients, decreased neutrophil count in three (6%) patients, infections in four (8%) patients, and diarrhoea in four (8%) patients. Ototoxicity occurred in one (2%) patient. One (2%) patient of the three who relapsed in this cohort died from disease. Two (4%) patients died in clinical remission after therapy discontinuation. One patient died of pneumonia and bacterial sepsis 1 year after therapy discontinuation and another patient died of unrelated causes 57 months after therapy completion. There were no treatment-related deaths.Minimal postoperative chemotherapy with two cycles of cisplatin, fluorouracil, and vincristine can ensure disease control in patients with hepatoblastoma resected at diagnosis. Our results show that dose reduction of ototoxic agents is a safe, effective treatment for these children.National Institutes of Health." @default.
• W2939723251 created "2019-04-25" @default.
• W2939723251 creator A5001429607 @default.
• W2939723251 creator A5025236828 @default.
• W2939723251 creator A5025991543 @default.
• W2939723251 creator A5034374604 @default.
• W2939723251 creator A5035520605 @default.
• W2939723251 creator A5049537528 @default.
• W2939723251 creator A5051981857 @default.
• W2939723251 creator A5053244337 @default.
• W2939723251 creator A5057959843 @default.
• W2939723251 creator A5060037035 @default.
• W2939723251 creator A5068381719 @default.
• W2939723251 creator A5073184572 @default.
• W2939723251 creator A5078125676 @default.
• W2939723251 creator A5079182398 @default.
• W2939723251 creator A5082223108 @default.
• W2939723251 creator A5089942191 @default.
• W2939723251 creator A5090325707 @default.
• W2939723251 date "2019-05-01" @default.
• W2939723251 modified "2023-10-16" @default.
• W2939723251 title "Minimal adjuvant chemotherapy for children with hepatoblastoma resected at diagnosis (AHEP0731): a Children's Oncology Group, multicentre, phase 3 trial" @default.
• W2939723251 cites W1746044287 @default.
• W2939723251 cites W1755690533 @default.
• W2939723251 cites W1938502624 @default.
• W2939723251 cites W1971211622 @default.
• W2939723251 cites W2016158954 @default.
• W2939723251 cites W2017061982 @default.
• W2939723251 cites W2036063485 @default.
• W2939723251 cites W2049440016 @default.
• W2939723251 cites W2107782019 @default.
• W2939723251 cites W2107972160 @default.
• W2939723251 cites W2156238103 @default.
• W2939723251 cites W2264584602 @default.
• W2939723251 cites W2326502969 @default.
• W2939723251 cites W2809505594 @default.
• W2939723251 cites W4293241248 @default.
• W2939723251 doi "https://doi.org/10.1016/s1470-2045(18)30895-7" @default.
• W2939723251 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6499702" @default.
• W2939723251 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30975630" @default.
• W2939723251 hasPublicationYear "2019" @default.
• W2939723251 type Work @default.
• W2939723251 sameAs 2939723251 @default.
• W2939723251 citedByCount "53" @default.
• W2939723251 countsByYear W29397232512019 @default.
• W2939723251 countsByYear W29397232512020 @default.
• W2939723251 countsByYear W29397232512021 @default.
• W2939723251 countsByYear W29397232512022 @default.
• W2939723251 countsByYear W29397232512023 @default.
• W2939723251 crossrefType "journal-article" @default.
• W2939723251 hasAuthorship W2939723251A5001429607 @default.
• W2939723251 hasAuthorship W2939723251A5025236828 @default.
• W2939723251 hasAuthorship W2939723251A5025991543 @default.
• W2939723251 hasAuthorship W2939723251A5034374604 @default.
• W2939723251 hasAuthorship W2939723251A5035520605 @default.
• W2939723251 hasAuthorship W2939723251A5049537528 @default.
• W2939723251 hasAuthorship W2939723251A5051981857 @default.
• W2939723251 hasAuthorship W2939723251A5053244337 @default.
• W2939723251 hasAuthorship W2939723251A5057959843 @default.
• W2939723251 hasAuthorship W2939723251A5060037035 @default.
• W2939723251 hasAuthorship W2939723251A5068381719 @default.
• W2939723251 hasAuthorship W2939723251A5073184572 @default.
• W2939723251 hasAuthorship W2939723251A5078125676 @default.
• W2939723251 hasAuthorship W2939723251A5079182398 @default.
• W2939723251 hasAuthorship W2939723251A5082223108 @default.
• W2939723251 hasAuthorship W2939723251A5089942191 @default.
• W2939723251 hasAuthorship W2939723251A5090325707 @default.
• W2939723251 hasBestOaLocation W29397232512 @default.
• W2939723251 hasConcept C126322002 @default.
• W2939723251 hasConcept C141071460 @default.
• W2939723251 hasConcept C143998085 @default.
• W2939723251 hasConcept C2776304256 @default.
• W2939723251 hasConcept C2776694085 @default.
• W2939723251 hasConcept C2776755627 @default.
• W2939723251 hasConcept C2779429289 @default.
• W2939723251 hasConcept C71924100 @default.
• W2939723251 hasConceptScore W2939723251C126322002 @default.
• W2939723251 hasConceptScore W2939723251C141071460 @default.
• W2939723251 hasConceptScore W2939723251C143998085 @default.
• W2939723251 hasConceptScore W2939723251C2776304256 @default.
• W2939723251 hasConceptScore W2939723251C2776694085 @default.
• W2939723251 hasConceptScore W2939723251C2776755627 @default.
• W2939723251 hasConceptScore W2939723251C2779429289 @default.
• W2939723251 hasConceptScore W2939723251C71924100 @default.
• W2939723251 hasIssue "5" @default.
• W2939723251 hasLocation W29397232511 @default.
• W2939723251 hasLocation W29397232512 @default.
• W2939723251 hasLocation W29397232513 @default.
• W2939723251 hasLocation W29397232514 @default.
• W2939723251 hasOpenAccess W2939723251 @default.
• W2939723251 hasPrimaryLocation W29397232511 @default.
• W2939723251 hasRelatedWork W1514766040 @default.
• W2939723251 hasRelatedWork W1969690025 @default.
• W2939723251 hasRelatedWork W2037924979 @default.
• W2939723251 hasRelatedWork W2047967234 @default.
• W2939723251 hasRelatedWork W2092503941 @default.
• W2939723251 hasRelatedWork W2324473769 @default.
• W2939723251 hasRelatedWork W2414534931 @default.

• next